Company Filing History:
1 out of 215 
1 out of 43 
1 out of 5,089 
Years Active: 2014
Title: Jean-Xavier Roca-Martinez: Innovator in Colorectal Cancer Treatment
Introduction
Jean-Xavier Roca-Martinez is a notable inventor based in Lyons, France. He has made significant contributions to the field of cancer research, particularly in the treatment of colorectal cancers. His innovative work has led to the development of specific antibodies that target human CK8, which plays a crucial role in identifying and treating this type of cancer.
Latest Patents
Roca-Martinez holds a patent for "Anti-CK8 antibodies to be used for treating colorectal cancers and identifying metastatic and/or invasive phenotypes." This invention relates to antibodies that are specific to human CK8 and includes pharmaceutical compositions aimed at preventing and treating colorectal cancers. Additionally, the patent outlines methods for identifying colorectal cancers with invasive and/or metastatic phenotypes by detecting the cleavage of the C-terminal portion of human CK8 on the surface of tumor cells. He has 1 patent to his name.
Career Highlights
Throughout his career, Roca-Martinez has worked with esteemed institutions such as Université Claude Bernard – Lyon 1 and Hospices Civils de Lyon. His research has been pivotal in advancing the understanding of colorectal cancer and developing targeted therapies.
Collaborations
Roca-Martinez has collaborated with notable colleagues, including Jean-Jacques Diaz and Jean-Christophe Saurin. These partnerships have further enriched his research and contributed to the advancements in cancer treatment.
Conclusion
Jean-Xavier Roca-Martinez is a distinguished inventor whose work in developing anti-CK8 antibodies has the potential to transform the treatment landscape for colorectal cancer. His contributions to medical research continue to pave the way for innovative therapies that can improve patient outcomes.